Abstract 2310: Targeting EP4 receptor on cancer cells and macrophages to abrogate stem-like functions, lymphangiogenesis and lymphatic metastasis in a breast cancer model.
Bibliographic record
Abstract
Abstract Background: We established that high COX-2 expression resulting in elevated prostaglandin (PG) E2 level in the tumor milieu promotes breast cancer progression and metastasis via multiple events: inactivation of immune cells, stimulation of tumor cell migration/invasiveness, tumor-associated angiogenesis and lymphangiogenesis. The lymphangiogenic action of COX-2 resulted from high VEGF-C/D production by tumor cells. These events were primarily due to activation of the PGE receptor EP4 on cancer cells, making it an excellent therapeutic target. Objectives: Present study tested the additional role of tumor-infiltrating macrophages in VEGF-C/D production and lymphangiogenesis in situ, the role of EP4 in stem-like tumor cell functions, and therapeutic effects of an EP4 antagonist. Since human cancer xenografts in immuno-compromised mice have limitations for preclinical testing, we developed a COX-2 expressing syngeneic murine breast cancer model of spontaneous lymphatic metastasis mimicking human and applied it for mechanistic and therapeutic studies. Methods and results: We tested the functional roles of COX-2 and EP4 in a highly metastatic COX-2 expressing murine breast cancer cell line C3L5. These cells expressed all EP receptors, produced VEGF-C and -D and showed high tumorsphere forming ability in ultra-low attachment plates by single cells for successive generations (surrogate of stem-like cell function) in vitro. Migration, tumorsphere formation and VEGF-C/D production by these cells were inhibited with Celecoxib or NS398 (COX-2 inhibitors) and a selective EP4 antagonist RQ-15986 (RaQualia Pharma). C3H/HeJ mice, when implanted SC in both inguinal regions with C3L5 cells suspended in growth factor-reduced Matrigel, exhibited rapid tumor growth, tumor-associated angiogenesis and lymphangiogenesis (respectively measured with CD31 and LYVE-1 immunostaining), metastasis to inguinal and axillary lymph nodes and the lungs. Tumors revealed high incidence of F4/ 80 +ve macrophages which also expressed EP4 and produced VEGF-C and -D in situ as evidenced by dual immunostaining of F4/80 and EP4, VEGF-C and -D. Chronic oral administration of Celecoxib or RQ-15986 at nontoxic doses abrogated tumor growth, lymphangiogenesis, angiogenesis, and metastasis to lymph nodes and lungs. Residual tumors in treated mice revealed markedly reduced VEGF-C/D proteins and incidence of VEGF-C/D +ve macrophages in situ. Conclusions: EP4 is an excellent therapeutic target to block stem-like properties, lymphangiogenesis induced by VEGF-C/D production by cancer cells and tumor infiltrating macrophages, deserving clinical testing for chemo-intervention in human breast cancer. (MM and XX contributed equally. Supported by grants of the CBCF, Ontario Chapter and the OICR to PKL, a TBCRU fellowship to MM and a gift of RQ-15986 by RaQualia Pharma). Citation Format: Mousumi Majumder, Xiping Xin, GannaReddy V. Girish, Peeyush K. Lala. Targeting EP4 receptor on cancer cells and macrophages to abrogate stem-like functions, lymphangiogenesis and lymphatic metastasis in a breast cancer model. [abstract]. In: Proceedings of the 104th Annual Meeting of the American Association for Cancer Research; 2013 Apr 6-10; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2013;73(8 Suppl):Abstract nr 2310. doi:10.1158/1538-7445.AM2013-2310
Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.
How this classification was reachedexpand
Full frame machine prediction
Teacher imitationNot calibrated prevalence, not ground truth. Human validation pending. The Gemma side is a direct model label for every work in the frame, read from the title-only record. The Codex side is a classifier learned from the 10,348 direct Codex labels and calibrated to design-weighted sample rates; fields without enough sample support carry no Codex call. Candidate is the union of the two sides; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels.
Distilled classifier scores by category (both heads)
| Category | Codex | Gemma |
|---|---|---|
| Metaresearch | 0.000 | 0.000 |
| Meta-epidemiology (narrow) | 0.001 | 0.000 |
| Meta-epidemiology (broad) | 0.000 | 0.000 |
| Bibliometrics | 0.000 | 0.000 |
| Science and technology studies | 0.000 | 0.000 |
| Scholarly communication | 0.000 | 0.000 |
| Open science | 0.000 | 0.000 |
| Research integrity | 0.000 | 0.001 |
| Insufficient payload (model declined to judge) | 0.001 | 0.000 |
Machine scores (provisional)
The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.
Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.
score_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from itClassification
machine, unvalidatedMachine predicted; a candidate call from one source (direct Gemma or distilled Codex), not a consensus.
How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".